Advice
in the absence of a submission from the holder of the marketing authorisation:
dasatinib (Sprycel®) is not recommended for use within NHSScotland.
Indication under review: the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia in combination with chemotherapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice392KB (PDF)
Medicine details
- Medicine name:
- dasatinib (Sprycel)
- SMC ID:
- SMC2192
- Indication:
- The treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia in combination with chemotherapy.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 May 2019